NasdaqGS:AMPH

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.


Snowflake Analysis

Flawless balance sheet and good value.


Similar Companies

Share Price & News

How has Amphastar Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AMPH's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.2%

AMPH

1.2%

US Pharmaceuticals

2.3%

US Market


1 Year Return

5.3%

AMPH

1.6%

US Pharmaceuticals

6.7%

US Market

Return vs Industry: AMPH exceeded the US Pharmaceuticals industry which returned 1.9% over the past year.

Return vs Market: AMPH matched the US Market which returned 6% over the past year.


Shareholder returns

AMPHIndustryMarket
7 Day-3.2%1.2%2.3%
30 Day7.1%-2.3%-0.7%
90 Day30.5%2.8%17.1%
1 Year5.3%5.3%4.3%1.6%9.0%6.7%
3 Year20.4%20.4%24.6%15.5%36.7%27.8%
5 Year21.1%21.1%27.5%12.8%65.2%46.9%

Price Volatility Vs. Market

How volatile is Amphastar Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Amphastar Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AMPH ($21.5) is trading below our estimate of fair value ($57.38)

Significantly Below Fair Value: AMPH is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AMPH is good value based on its PE Ratio (19.4x) compared to the Pharmaceuticals industry average (20.8x).

PE vs Market: AMPH is poor value based on its PE Ratio (19.4x) compared to the US market (16.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AMPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AMPH is good value based on its PB Ratio (2.6x) compared to the US Pharmaceuticals industry average (3.4x).


Next Steps

Future Growth

How is Amphastar Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

15.7%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if AMPH's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if AMPH's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AMPH's revenue (15.7% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: AMPH's revenue (15.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AMPH's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Amphastar Pharmaceuticals performed over the past 5 years?

59.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AMPH has a large one-off gain of $59.9M impacting its March 31 2020 financial results.

Growing Profit Margin: AMPH's current net profit margins (15.9%) are higher than last year (0.9%).


Past Earnings Growth Analysis

Earnings Trend: AMPH has become profitable over the past 5 years, growing earnings by 59.1% per year.

Accelerating Growth: AMPH's earnings growth over the past year (1739.8%) exceeds its 5-year average (59.1% per year).

Earnings vs Industry: AMPH earnings growth over the past year (1739.8%) exceeded the Pharmaceuticals industry 16.1%.


Return on Equity

High ROE: AMPH's Return on Equity (12.3%) is considered low.


Next Steps

Financial Health

How is Amphastar Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: AMPH's short term assets ($246.7M) exceed its short term liabilities ($83.4M).

Long Term Liabilities: AMPH's short term assets ($246.7M) exceed its long term liabilities ($66.1M).


Debt to Equity History and Analysis

Debt Level: AMPH's debt to equity ratio (11.1%) is considered satisfactory.

Reducing Debt: AMPH's debt to equity ratio has reduced from 17.3% to 11.1% over the past 5 years.

Debt Coverage: AMPH's debt is well covered by operating cash flow (99.4%).

Interest Coverage: AMPH earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Amphastar Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AMPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AMPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AMPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AMPH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AMPH's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

17.5yrs

Average management tenure


CEO

Jack Zhang (73yo)

24.5yrs

Tenure

US$5,969,742

Compensation

Dr. Yongfeng Zhang, also known as Jack, Ph.D., serves as President at Amphastar Pharmaceuticals, Inc. since April 10, 2020. He co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive  ...


CEO Compensation Analysis

Compensation vs Market: Jack's total compensation ($USD5.97M) is above average for companies of similar size in the US market ($USD3.16M).

Compensation vs Earnings: Jack's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Ziping Luo
Chairman of the Board24.5yrsUS$2.98m2.91% $28.9m
Yongfeng Zhang
Co-founder24.5yrsUS$5.97m4.33% $43.0m
William Peters
CFO, Treasurer & Senior VP of Finance6.25yrsUS$1.96m0.053% $530.6k
Rong Zhou
Executive Vice President of Production Center5.08yrsUS$1.13m0.31% $3.1m
Jacob Liawatidewi
Executive VP of Corporate Administration Centerno datano data0.026% $260.6k
Dan Dischner
Vice President of Corporate Communicationsno datano datano data
Peter Langosh
Vice President of Operational Improvement and Vice President of Internal Audit19.5yrsUS$162.64kno data
Eva Wen
Director of System Control15.5yrsno datano data
Tony Marrs
Vice President of Clinical Researchno datano datano data

17.5yrs

Average Tenure

64yo

Average Age

Experienced Management: AMPH's management team is seasoned and experienced (17.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ziping Luo
Chairman of the Board24.5yrsUS$2.98m2.91% $28.9m
Yongfeng Zhang
Co-founder24.5yrsUS$5.97m4.33% $43.0m
Richard Prins
Lead Independent Director1.25yrsUS$313.01k0.073% $727.1k
Shiren S. Lee
Independent Director12.92yrsUS$299.51k0.28% $2.7m
Chen Yang
Member of Scientific Advisory Boardno datano datano data
Paul White
Member of Scientific Advisory Boardno datano datano data
Gordon Treweek
Member of Scientific Advisory Boardno datano datano data
Herschel Rabitz
Member of Scientific Advisory Boardno datano datano data
Richard Porter
Member of Scientific Advisory Boardno datano datano data
Richard Koo
Independent Director16.92yrsUS$310.01k0.55% $5.4m

16.9yrs

Average Tenure

71.5yo

Average Age

Experienced Board: AMPH's board of directors are seasoned and experienced ( 16.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AMPH insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Amphastar Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Amphastar Pharmaceuticals, Inc.
  • Ticker: AMPH
  • Exchange: NasdaqGS
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$993.264m
  • Shares outstanding: 46.20m
  • Website: https://www.amphastar.com

Number of Employees


Location

  • Amphastar Pharmaceuticals, Inc.
  • 11570 6th Street
  • Rancho Cucamonga
  • California
  • 91730
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AMPHNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2014
29ADB (Deutsche Boerse AG)YesCommon StockDEEURJun 2014

Biography

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; naloxone for opioid overdose; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; and Cortrosyn, a lyophilized powder use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; lidocaine jelly, a local anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection for newborn babies; atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; morphine injection; and lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as recombinant human insulin API (active pharmaceutical ingredients) and porcine insulin API. Further, the company has a pipeline of 20 product candidates in various stages of development for various indications. It serves hospitals, care facilities, alternate care sites, clinics, and doctors’ offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/08 23:57
End of Day Share Price2020/07/08 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.